Introduction
============

Esophageal cancer is the eighth type of cancer most frequently diagnosed and the sixth leading cause of death in the world ([@b1-ol-0-0-11122]). Despite advances in surgical techniques, postoperative managements, and treatment strategies, the mortality rate of esophageal cancer remains high and the 5-year survival rate was reported to range from 15 to 25% ([@b2-ol-0-0-11122],[@b3-ol-0-0-11122]). In Japan, neoadjuvant chemotherapy (NAC) with a combination of cisplatin plus 5-fluorouracil (FP) followed by surgery is a standard treatment strategy for resectable stage II/III esophageal squamous cell carcinoma (ESCC) ([@b4-ol-0-0-11122]). However, in patients who respond unfavorably, the inefficient preoperative therapy should be discontinued and surgery should not be delayed. Conversely, patients who respond favorably to preoperative therapy may benefit from additional preoperative treatment. Thus, it is important to establish a method that may be used to predict the pathological response to NAC reliably to prevent wasting time and improve surgical outcomes.

Recently, several systemic immuno-inflammatory responses have been reported to be independent prognostic biomarkers in many types of malignancies, such as stomach, colon, hepatic, lung, and esophageal cancers ([@b5-ol-0-0-11122]--[@b11-ol-0-0-11122]). However, the clinical impact of these systemic immuno-inflammatory responses modulated by NAC on the response to NAC for esophageal cancer remains unclear.

In this study, we investigated the clinical significance of changes in systemic immuno-inflammatory measures during NAC in terms of the response to NAC and long-term outcomes in patients with esophageal cancer.

Materials and methods
=====================

### Patients

A total of 85 consecutive patients underwent a transthoracic esophagectomy for clinical stage II or III esophageal cancer at the National Defense Medical College Hospital (Saitama, Japan) between January 2009 and December 2014. All patients were administered NAC before esophagectomy. Among the 85 patients, 9 (11%) were women and 76 (89%) were men. The mean age was 68.6±0.9 years (range, 43--86 years). The tumor node metastasis criteria from the eighth edition of the Union for International Cancer Control classification system were used for tumor staging ([@b12-ol-0-0-11122]). All patients were intended to be administered 2 courses of NAC before esophagectomy. Patients who failed to complete 2 courses of NAC were excluded from this study. All patients including clinically stage IV were considered to be resectable after NAC and underwent the resection with curative intent. Patients who underwent the palliative surgery, such as salvage surgery or bypass surgery, were excluded from this study. Among the 85 patients, 7 patients could not achieve oral intake because of the obstructing locally advanced esophageal cancer, and underwent laparoscopic jejunostomy and adequate enteral nutrition during NAC ([@b13-ol-0-0-11122]).

Neutrophil count, platelet count, lymphocyte count, CRP level, albumin concentration, and psoas mass index (PMI) were evaluated before and after NAC. The neutrophil-to-lymphocyte ratio (NLR) was defined as the absolute neutrophil count divided by the absolute lymphocyte count, the platelet-to-lymphocyte ratio (PLR) was defined as the absolute platelet count divided by the absolute lymphocyte count, and the C-reactive protein-to-albumin ratio (CAR) was calculated by dividing the serum CRP level by the serum albumin level. PMI (cm^2^/m^2^) was calculated by dividing the area of the psoas muscle at the third lumbar vertebra in a cross-sectional computed tomography (CT) image by height squared as previously described ([@b14-ol-0-0-11122]). The blood test after NAC was performed one month after the last chemotherapy and just before the operation. No patients were administered granulocyte-colony stimulating factor during NAC, which should affect the immuno-inflammatory markers.

The association between patient demographics (information obtained from our computer database) and overall survival (OS) was evaluated in patients with esophageal cancer. OS was measured from the date of esophagectomy to the date of death from any cause. Patients who survived were defined to be censored in our survival analyses. All patients were observed at our hospital or outpatient clinic at 3- to 4-month intervals during the first two years of the study, and every 6 or 12 months thereafter for three years. A CT scan was performed, and tumor markers were assessed every 6 months until five years after the resection. Five years after surgery, annual follow-ups were conducted by telephone with the patients, the patient\'s family members, or their practitioners. The Institutional Review Board of the National Defense Medical College Hospital approved this protocol. All patients provided written informed consent prior to their inclusion in the study.

### NAC and surgical procedure

All patients were intended to be administered two courses of NAC before esophagectomy. FP chemotherapy was repeated twice every 3 weeks with a dose of 80 mg/m^2^ of cisplatin was given by intravenous drip infusion on day one and 5-fluorouracil was administered at a dose of 800 mg/m^2^ by continuous infusion on days one through five. Esophageal resection was performed approximately one month after the last infusion.

In the open surgery patients, open transthoracic esophagectomy was performed through the right fifth or sixth thoracotomy with adequate lymphadenectomy. In the video-assisted surgery patients, thoracoscopic esophagectomy was performed using three ports with diameters of 12 mm as described previously ([@b15-ol-0-0-11122]). Gastric tube reconstruction was performed by laparoscopy-assisted surgery in all patients ([@b16-ol-0-0-11122]).

### Histopathological response assessment

Histopathological response was graded into five groups. Grade 0 response indicated no evidence of effect, Grade 1a response indicated very slight effect (viable tumor cells occupy more than 2/3 of the tumorous area), Grade 1b response indicated slight effect (viable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area), Grade 2 response indicated considerable effect (viable tumor cells remain in less than 1/3 of the tumorous area), and Grade 3 response indicated complete response ([@b12-ol-0-0-11122]).

### Statistical analysis

Statistical analyses were performed using the Mann-Whitney *U* or chi-square tests. The Kaplan-Meier method was used to make the OS curve, and the survival differences were compared with the log-rank test. A multivariate analysis was performed with the Cox proportional hazards model, and prognostic variables were introduced in the model when the univariate analysis revealed a significance level of P\<0.05. All values with P\<0.05 were statistically significant. A time-dependent receiver operating characteristics (ROC) curve for censored survival outcomes was constructed to estimate the optimal cutoff value of the inflammatory-nutritional measures before NAC in [Tables I](#tI-ol-0-0-11122){ref-type="table"} and [II](#tII-ol-0-0-11122){ref-type="table"}. JMP 12.0 (SAS Institute Inc., Cary, NC, USA) was used to perform all analyses.

Results
=======

The prediction of the pathological responses using pretherapeutic inflammatory-nutritional measures is presented in [Table I](#tI-ol-0-0-11122){ref-type="table"}. The pretherapeutic NLR was a significant predictive marker of the pathological response to NAC. However, pretherapeutic PLR, CAR, and PMI had no influence on pathological responses to NAC. Among the individual components of the systemic immuno-inflammatory parameters, high neutrophil counts before NAC were associated with a favorable pathological response to NAC ([Table II](#tII-ol-0-0-11122){ref-type="table"}). However, this correlation was not observed with lymphocyte, platelet, CRP, and albumin levels.

The NLR and PMI decreased significantly after NAC; such decreases were not observed in the PLR and CAR ([Fig. 1](#f1-ol-0-0-11122){ref-type="fig"}). Additionally, the neutrophil and platelet counts were significantly decreased after NAC. However, no changes in lymphocyte count, CRP levels, and albumin levels were reported during NAC ([Fig. 2](#f2-ol-0-0-11122){ref-type="fig"}).

Clinicopathological characteristics were compared between patients grouped based on changes in the NLR, PLR, CAR, and PMI after NAC ([Table III](#tIII-ol-0-0-11122){ref-type="table"}). Patients with a decreased NLR after NAC had pStage III/IV diseases more frequently. Additionally, patients with a decreased CAR after NAC had a better histopathological response to NAC compared to those with an increased CAR. There were no correlations among gender, age, surgical procedure, tumor depth, lymph node metastasis, tumor location, histological type, tumor differentiation, or response to NAC with the changes in the NLR, PLR, CAR, and PMI after NAC. There were no correlations between the postoperative complications and the changes in the NLR, PLR, CAR, and PMI after NAC ([Table SI](#SD1-ol-0-0-11122){ref-type="supplementary-material"}).

Clinicopathological characteristics were compared between patients who were grouped according to changes in the individual components of the systemic immuno-inflammatory measures, i.e., neutrophil, lymphocyte, and platelet counts; and CRP and albumin levels after NAC ([Table IV](#tIV-ol-0-0-11122){ref-type="table"}). There were no relationships between clinicopathological features and changes in the individual components of the systemic immuno-inflammatory measures, except that patients with decreased neutrophil counts after NAC had a better histological response.

Patients with a decreased NLR after NAC had a significantly favorable OS compared to those with an increased NLR; however, such differences were not observed with changes in the PLR, CAR, and PMI ([Fig. 3](#f3-ol-0-0-11122){ref-type="fig"}). Similarly, patients with a decreased neutrophil count after NAC had a significantly favorable OS compared to those with an increased neutrophil count; however, such differences were not observed in the changes in lymphocyte and platelet counts and CRP and albumin levels ([Fig. 4](#f4-ol-0-0-11122){ref-type="fig"}).

Univariate and multivariate analyses of factors that might affect OS were performed separately for immune-inflammatory measures ([Table V](#tV-ol-0-0-11122){ref-type="table"}) and their individual components ([Table VI](#tVI-ol-0-0-11122){ref-type="table"}) due to their confounding. In the univariate analysis, the pathological stage and decreased NLR after NAC were significantly associated with favorable OS ([Table V](#tV-ol-0-0-11122){ref-type="table"}). The multivariate analysis demonstrated that only a decreased NLR after NAC was significantly associated with favorable OS. Both the univariate and multivariate analyses, including the individual components of the systemic immuno-inflammatory parameters demonstrated that the pathological stage and decreased neutrophil count after NAC were significantly associated with favorable OS ([Table VI](#tVI-ol-0-0-11122){ref-type="table"}).

Discussion
==========

The present study is the first report to evaluate the predictive value of the changes of various systemic immuno-inflammatory and nutritional parameters on the therapeutic effects of NAC and long-term outcomes in patients with esophageal cancer. In this study, we demonstrated that patients with high neutrophil counts before NAC had better histopathological responses to NAC. Additionally, we reported that decreases in the NLR and neutrophil counts after NAC were significant predictors of OS in patients with resectable stage II/III esophageal cancer.

Although many studies have shown that systemic immuno-inflammatory and nutritional parameters are useful predictors of long-term outcomes, there are conflicting results between these parameters and the response to NAC ([@b5-ol-0-0-11122],[@b17-ol-0-0-11122],[@b18-ol-0-0-11122]). Sato *et al* ([@b19-ol-0-0-11122]) reported that esophageal cancer patients with a lower NLR before NAC had a better response to NAC than those with a higher NLR. There have been similar reports for several malignancies ([@b20-ol-0-0-11122],[@b21-ol-0-0-11122]). Conversely, Lorente *et al* ([@b22-ol-0-0-11122]) and Graziano *et al* ([@b23-ol-0-0-11122]) did not find any significance of NLR as a predictor of the response to NAC in breast cancer. In addition, our present study demonstrated that a pretherapeutic higher values of NLR and neutrophil count were related to a better response to NAC in esophageal cancer patients. In addition, we previously reported that the pretherapeutic higher values of NLR and CAR were associated with unfavorable outcome ([@b11-ol-0-0-11122]). It is well known that immuno-inflammatory parameters are easily affected by various factors, such as obstruction of the tumor, anti-platelet drug use, smoking history, and co-morbidities ([@b11-ol-0-0-11122]). Thus, we believe that it is important to examine the changes in immuno-inflammatory parameters modulated by NAC because there is a limitation to predicting the response of NAC by these parameters just before NAC.

Konishi *et al* ([@b24-ol-0-0-11122]) reported that the severe neutrophil decline after NAC is associated with a high histological response in esophageal cancer, which is consistent with our present results. There are also several reports describing how hematological toxicity is correlated with a better response to NAC in breast and colorectal cancers ([@b25-ol-0-0-11122],[@b26-ol-0-0-11122]). The therapeutic effects of NAC for cancer cells depend on whether a sufficient amount of therapeutic agents can reach the cancer cells or whether the tumor is sensitive to these agents. The same is true of healthy cells, particularly hematopoietic cells. Thus, it is reasonable that hematological toxicity is correlated with the response to chemotherapy ([@b27-ol-0-0-11122]).

In the present study, we presented that a significant decline in the NLR after NAC was associated with favorable OS and a better NAC response in patients with esophageal cancer. Lee *et al* ([@b28-ol-0-0-11122]) also demonstrated that a significant reduction in the NLR after chemotherapy is associated with a better tumor response and a favorable outcome in advanced lung cancer patients. However, Konishi *et al* ([@b24-ol-0-0-11122]) did not find a correlation between the grade of neutropenia and survival outcome, although the severe neutrophil decline after NAC was correlated with a high histological response. For this reason, they speculated that severe neutropenia itself caused treatment-related death and was associated with worse long-term outcomes.

PMI is a nutritional parameter and a marker of sarcopenia that was recently reported for its prognostic value in many malignancies ([@b29-ol-0-0-11122],[@b30-ol-0-0-11122]). Liu *et al* ([@b31-ol-0-0-11122]) reported that a declined PMI after NAC was associated with a poor prognosis in patients with esophageal cancer. In our previous study, we found that decline of PMI until 6 months after esophagectomy was independently associated with the incidence of pneumonia 6 months after resection for esophageal cancer ([@b32-ol-0-0-11122]). In this study, NAC decreased the PMI, but we could not find the relationship between changes in the PMI during NAC and survival outcomes.

The present study was conducted at a single institution using a retrospective design, a relatively small number of patients, and was not included the dose intensity and non-hematological adverse events of NAC, which are limitations of this study. Therefore, prospective studies with more patients are warranted to validate the results of this study.

In conclusion, among various systemic immuno-inflammatory and nutritional parameters, a decreased NLR and decreased neutrophil counts after NAC had clinical significance as predictors of the response to NAC and of survival, respectively, in esophageal cancer. Predicting responses to NAC at the early phase of treatment, especially selecting non-responders, is significantly important to reduce unnecessary chemotherapy or convert the treatment to surgery before tumor progression. The systemic immune-inflammatory and nutritional measures may help predicting the efficacy of NAC to carefully investigate these changes during NAC.
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###### 

Association between pretreatment NLR, PLR, CAR and PMI measures and histopathological response to NAC.

                            NLR, n (%)             PLR, n (%)            CAR, n (%)          PMI (number, %)                                        
  --------------- --------- ------------ --------- ------------ -------- ------------ ------ ----------------- --------- ------ --------- --------- ------
    Grade 0, 1a   73 (85)   56 (92)      17 (71)   0.03         9 (90)   64 (85)      1.00   19 (90)           54 (84)   0.72   29 (40)   44 (60)   0.34
    Grade \>1b    12 (15)   5 (8)        7 (29)                 1 (10)   11 (15)             2 (10)            10 (16)          7 (58)    5 (42)    

NAC, neoadjuvant chemotherapy; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C-reactive protein-to-albumin ratio; PMI, psoas muscle index.

###### 

Association between pretreatment individual components of systemic immuno-inflammatory measures and histopathological response to NAC.

                          Neutrophil, n (%)             Lymphocyte, n (%)              Platelet, n (%)          CRP, n (%)              Albumin, n (%)                                                   
  ------------- --------- ------------------- --------- ------------------- ---------- ----------------- ------ ------------ ---------- ---------------- --------- ---------- ------ --------- --------- ------
  Grade 0, 1a   73 (85)   46 (94)             27 (75)   0.02                38 (83)    35 (89)           0.53   59 (85)      14 (88)    \>0.99           30 (91)   43 (83)    0.35   55 (83)   18 (95)   0.28
  Grade \>1b    12 (15)   3 (6)               9 (25)                          8 (17)   4 (11)                   10 (15)        2 (12)                    3 (9)       9 (17)          11 (17)   1 (5)     

NAC, neoadjuvant chemotherapy; CRP, C-reactive protein.

###### 

Clinicopathological characteristics according to the NLR, PLR, CAR and PMI measures.

                                       NLR, n (%)              PLR, n (%)              CAR, n (%)            PMI, n (%)                                             
  ------------------------- ---------- ------------ ---------- ------------ ---------- ------------ -------- ------------ ---------- -------- ---------- ---------- --------
  Sex                                                          0.48                                 0.73                             \>0.99                         0.46
    Female                  9 (11)     7 (13)       2 (7)                   5 (10)     4 (12)                6 (11)       3 (9)               5 (9)      4 (14)     
    Male                    76 (89)    48 (87)      28 (93)                 47 (90)    29 (88)               47 (89)      29 (91)             52 (91)    24 (86)    
  Age, years                                                   0.69                                 0.27                             0.16                           0.35
    mean ± SD               68.6±0.9   68.8±1.1     68.1±1.5                69.4±1.1   67.3±1.4              67.6±1.1     70.2±1.4            69.2±1.1   67.3±1.6   
  Surgical procedure                                           0.65                                 \>0.99                           \>0.99                         0.18
    Open                    34 (40)    21 (38)      13 (43)                 21 (41)    13 (40)               21 (40)      13 (41)             20 (35)    14 (50)    
    Video-assisted          51 (60)    34 (62)      17 (56)                 31 (59)    20 (60)               32 (60)      19 (59)             37 (65)    14 (50)    
  T stage                                                      0.58                                 \>0.99                           0.57                           0.40
    T1/2                    17 (20)    10 (18)      7 (23)                  10 (19)    7 (21)                12 (23)      5 (16)              13 (23)    4 (14)     
    T3/4                    68 (80)    45 (82)      23 (77)                 42 (81)    26 (79)               41 (78)      27 (84)             44 (77)    24 (86)    
  Lymph node metastasis                                        0.34                                 \>0.99                           0.35                           0.81
    N0/1                    55 (65)    38 (69)      17 (57)                 34 (65)    21 (64)               32 (60)      23 (72)             36 (63)    19 (68)    
    N2/3                    30 (35)    17 (31)      13 (43)                 18 (35)    12 (36)               21 (40)      9 (28)              21 (37)    9 (32)     
  pTNM stage                                                   0.02                                 \>0.99                           0.45                           0.44
    I/II                    24 (28)    20 (36)      4 (13)                  15 (29)    9 (27)                17 (32)      7 (22)              18 (32)    6 (21)     
    III/IV                  61 (72)    35 (64)      26 (87)                 37 (71)    24 (73)               36 (68)      25 (78)             39 (68)    22 (79)    
  Tumor location                                               0.49                                 0.26                             \>0.99                         0.64
    Upper/Middle            49 (58)    30 (55)      19 (63)                 27 (52)    22 (67)               31 (58)      18 (56)             34 (60)    15 (54)    
    Lower                   36 (42)    25 (45)      11 (37)                 25 (48)    11 (33)               22 (42)      14 (44)             23 (40)    13 (46)    
  Tumor type                                                   \>0.99                               0.52                             0.13                           \>0.99
    Adenocarcinoma/Others   2 (2)      1 (2)        1 (3)                   2 (4)      0 (0)                 0 (0)        2 (6)               1 (2)      1 (4)      
    Squamous                83 (98)    54 (98)      29 (97)                 50 (96)    33 (100)              53 (100)     30 (94)             56 (98)    27 (96)    
  Tumor differentiation                                        0.56                                 0.57                             \>0.99                         \>0.99
    Well/Moderate           69 (81)    46 (84)      23 (77)                 41 (79)    28 (85)               43 (81)      26 (81)             47 (81)    22 (79)    
    Poor                    16 (19)    9 (16)       7 (23)                  11 (21)    5 (15)                10 (19)      6 (19)              10 (19)    6 (21)     
  Histological response                                        0.53                                 0.20                             0.02                           0.74
    Grade 0, 1a             73 (86)    46 (84)      27 (90)                 47 (90)    26 (79)               42 (79)      31 (97)             48 (84)    25 (89)    
    Grade 1b,2,3            12 (14)    9 (16)       3 (10)                  5 (10)     7 (21)                11 (21)      1 (3)               9 (16)     3 (11)     
  RECIST                                                       0.23                                 0.70                             \>0.99                         \>0.99
    PR,CR                   78 (92)    52 (95)      26 (87)                 47 (90)    31 (94)               49 (92)      29 (91)             52 (91)    26 (93)    
    SD,PD                   7 (8)      3 (5)        4 (13)                  5 (10)     2 (6)                 4 (8)        3 (9)               5 (9)      2 (7)      

NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C-reactive protein-to-albumin ratio; PMI, psoas muscle index; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease.

###### 

Clinicopathological characteristics according to individual components of systemic immuno-inflammatory measures.

                                       Neutrophil, n (%)              Lymphocyte, n (%)              Platelet, n (%)            CRP, n (%)              Albumin, n (%)s                                                        
  ------------------------- ---------- ------------------- ---------- ------------------- ---------- ----------------- -------- ------------ ---------- ----------------- ---------- ---------- -------- ---------- ---------- ------
  Sex                                                                 0.83                                             0.73                             0.28                                    0.49                           0.49
    Female                  9 (11)     6 (11)              3 (10)                         4 (9)      5 (12)                     4 (8)        5 (16)                       8 (12)     1 (5)               6 (13)     3 (8)      
    Male                    76 (89)    48 (89)             28 (90)                        40 (91)    36 (88)                    49 (92)      27 (84)                      57 (88)    19 (95)             40 (87)    36 (92)    
  Age, years                                                          0.94                                             0.08                             0.37                                    0.72                           0.50
    mean ± SD               68.6±0.9   68.5±1.1            68.7±1.5                       67.0±1.2   70.2±1.2                   67.9±1.1     69.6±1.4                     68.4±1     69.2±1.8            69.1±1.2   67.9±1.3   
  Surgical procedure                                                  0.49                                             0.65                             0.82                                    \>0.99                         0.51
    Open                    34 (40)    20 (37)             14 (45)                        19 (43)    15 (37)                    22 (42)      12 (38)                      26 (40)    8 (40)              20 (43)    14 (36)    
    Video-assisted          51 (60)    34 (63)             17 (55)                        25 (57)    26 (63)                    31 (58)      20 (62)                      39 (60)    12 (60)             26 (57)    25 (64)    
  T stage                                                             0.39                                             \>0.99                           \>0.99                                  0.06                           0.10
    T1/2                    17 (20)    9 (17)              8 (26)                         9 (20)     8 (20)                     11 (21)      6 (19)                       16 (24)    1 (5)               6 (13)     11 (28)    
    T3/4                    68 (80)    45 (83)             23 (74)                        35 (80)    33 (80)                    42 (79)      26 (81)                      49 (76)    19 (95)             40 (87)    28 (72)    
  Lymph node metastasis                                               \>0.99                                           \>0.99                           \>0.99                                  0.30                           0.17
    N0/1                    55 (65)    35 (65)             20 (65)                        28 (64)    27 (66)                    34 (64)      21 (66)                      40 (62)    15 (75)             33 (72)    22 (56)    
    N2/3                    30 (35)    19 (35)             11 (35)                        16 (36)    14 (34)                    19 (36)      11 (34)                      25 (38)    5 (25)              13 (28)    17 (44)    
  TNM stage                                                           0.08                                             0.81                             0.80                                    0.41                           0.23
    I/II                    24 (28)    19 (35)             5 (16)                         13 (30)    11 (27)                    16 (30)      8 (25)                       20 (31)    4 (20)              10 (22)    14 (36)    
    III/IV                  61 (72)    35 (65)             26 (84)                        31 (70)    30 (73)                    37 (70)      24 (75)                      45 (69)    16 (80)             36 (78)    25 (64)    
  Tumor location                                                      0.65                                             \>0.99                           0.26                                    \>0.99                         0.06
    Upper/Middle            49 (58)    30 (56)             19 (61)                        25 (57)    24 (59)                    28 (52)      21 (66)                      37 (57)    12 (60)             22 (48)    27 (69)    
    Lower                   36 (42)    24 (44)             12 (39)                        19 (43)    17 (41)                    25 (47)      11 (34)                      28 (43)    8 (40)              24 (52)    12 (31)    
  Tumor type                                                          \>0.99                                           0.49                             0.52                                    0.06                           0.49
    Adenocarcinoma/Others   2 (2)      1 (2)               1 (3)                          2 (5)      0 (0)                      2 (4)        0 (0)                        0 (0)      2 (10)              2 (4)      0 (0)      
    Squamous                83 (98)    53 (98)             30 (97)                        42 (95)    41 (100)                   51 (96)      32 (100)                     65 (100)   18 (90)             44 (96)    39 (100)   
  Tumor differentiation                                               0.25                                             0.58                             0.58                                    \>0.99                         0.41
    Well/Moderate           69 (81)    46 (85)             23 (74)                        37 (84)    32 (78)                    44 (83)      25 (78)                      53 (82)    16 (80)             39 (85)    30 (77)    
    Poor                    16 (19)    8 (15)              8 (26)                         7 (16)     9 (22)                     9 (17)       7 (22)                       12 (18)    4 (20)              7 (15)     9 (23)     
  Histological response                                               0.04                                             0.12                             0.52                                    0.06                           0.13
    Grade 0, 1a             73 (86)    43 (80)             30 (97)                        35 (80)    38 (93)                    44 (83)      29 (91)                      53 (82)    20 (100)            42 (91)    31 (79)    
    Grade 1b, 2, 3          12 (14)    11 (20)             1 (3)                          9 (20)     3 (7)                      9 (17)       3 (9)                        12 (18)    0 (0)               4 (9)      8 (21)     
  RECIST                                                              0.25                                             0.70                             \>0.99                                  0.66                           0.44
    PR                      78 (92)    51 (94)             27 (87)                        41 (93)    37 (90)                    49 (92)      29 (91)                      60 (92)    18 (90)             41 (89)    37 (95)    
    SD,PD                   7 (8)      3 (6)               4 (13)                         3 (7)      4 (10)                     4 (8)        3 (9)                        5 (8)      2 (10)              5 (11)     2 (5)      

CRP, C-reactive protein; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Univariate and multivariate analyses for association between overall survival of patients with esophageal cancer and NLR, PLR CAR and PMI.

  Variable                     Univariate analysis, HR (95% CI)   P-value   Multivariate analysis, HR (95% CI)   P-value
  ---------------------------- ---------------------------------- --------- ------------------------------------ ---------
  Sex                                                                                                            
    Female                     Ref.                               0.420                                          
    Male                       1.483 (0.603--4.920)                                                              
  Age, years+1                 2.285 (0.473--12.45)               0.320                                          
  Surgical procedure                                                                                             
    Open                       Ref.                               0.830                                          
    Video-assisted             0.944 (0.543--1.663)                                                              
  p stage                                                                                                        
    Stage1-2                   Ref.                               0.030     Ref.                                 0.070
    Stage3-4                   2.06 (1.093--4.227)                          1.811 (0.948--3.752)                 
  Tumor location                                                                                                 
    Lower/middle               Ref.                               0.210                                          
    Upper                      1.554 (0.735--2.978)                                                              
  Tumor differentiation                                                                                          
    Well/moderate              Ref.                               0.080                                          
    Poor                       1.794 (0.915--3.300)                                                              
  Histopathological response                                                                                     
    Grade 1a                   Ref.                               0.650                                          
    \>Grade 1b                 1.181 (0.538--2.316)                                                              
  NLR                                                                                                            
    Increased                  Ref.                               0.009     Ref.                                 0.020
    Decreased                  0.468 (0.270--0.822)                         0.5200 (0.296--0.920)                
  PLR                                                                                                            
    Increased                  Ref.                               0.749                                          
    Decreased                  0.9099 (0.521--1.623)                                                             
  CAR                                                                                                            
    Increased                  Ref.                               0.301                                          
    Decreased                  1.357 (0.771--2.482)                                                              
  PMI                                                                                                            
    Increased                  Ref.                               0.790                                          
    Decreased                  0.92 (0.528--1.673)                                                               

HR, hazard ratio; Ref., reference; pStage, pathological stage; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, C-reactive protein-to-albumin ratio; PMI, psoas muscle index.

###### 

Univariate and multivariate analyses of overall survival of patients with esophageal cancer and neutrophil, lymphocyte, platelet, CRP and Alb levels.

  Variable                     Univariate analysis, HR (95% CI)   P-value   Multivariate analysis, HR (95% CI)   P-value
  ---------------------------- ---------------------------------- --------- ------------------------------------ ---------
  Sex                                                                                                            
    Female                     Ref.                               0.420                                          
    Male                       1.483 (0.603--4.920)                                                              
  Age (years+1)                2.285 (0.473--12.45)               0.320                                          
  Surgical procedure                                                                                             
    Open                       Ref.                               0.830                                          
    Video-assisted             0.944 (0.543--1.663)                                                              
  p stage                                                                                                        
    Stage1-2                   Ref.                               0.030     Ref.                                 0.049
    Stage3-4                   2.06 (1.093--4.227)                          1.899 (1.002--3.913)                 
  Tumor location                                                                                                 
    Lower/middle               Ref.                               0.210                                          
    Upper                      1.554 (0.735--2.978)                                                              
  Tumor differentiation                                                                                          
    Well/moderate              Ref.                               0.080                                          
    Poor                       1.794 (0.915--3.300)                                                              
  Histopathological response                                                                                     
    Grade 1a                   Ref.                               0.650                                          
    \>Grade 1b                 1.181 (0.538--2.316)                                                              
  Neutrophil                                                                                                     
    Increased                  Ref.                               0.010     Ref.                                 0.022
    Decreased                  0.484 (0.279--0.846)                         0.519 (0.298--0.910)                 
  Lymphocyte                                                                                                     
    Increased                  Ref.                               0.395                                          
    Decreased                  1.268 (0.731--2.206)                                                              
  Platelet                                                                                                       
    Increased                  Ref.                               0.841                                          
    Decreased                  0.944 (0.544--1.678)                                                              
  CRP (mg/dl)                                                                                                    
    Increased                  Ref.                               0.175                                          
    Decreased                  0.641 (0.354--1.232)                                                              
  Alb                                                                                                            
    Increased                  Ref.                               0.504                                          
    Decreased                  0.830 (0.479--1.436)                                                              

HR, hazard ratio; Ref., reference; pStage, pathological stage; CRP, C-reactive protein; Alb, albumin.
